Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancerZhiyong Wang, J. Silvio Gutkind, Umamaheswar Duvvuri et al.|Nature Communications|2021Cited by 86
Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma PatientsUmamaheswar Duvvuri, Julie E. Bauman, Jonathan George et al.|Clinical Cancer Research|2019Cited by 42
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinomaKara D. Meister, Umamaheswar Duvvuri, Neal R. Godse et al.|Scientific Reports|2019Cited by 19
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck CancerJulie E. Bauman, Roger B. Cohen, Ricklie Julian et al.|Cancers|2022Cited by 11
Genomic Correlates of Exceptional Response to ErbB3 Inhibition in Head and Neck Squamous Cell CarcinomaDaniel L. Faden, Umamaheswar Duvvuri, Roberto Gomez-Casal et al.|JCO Precision Oncology|2019Cited by 3